文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

药物基因组学在罕见病中的作用

The Role of Pharmacogenomics in Rare Diseases.
PubMed 文献 · Drug Saf · 2024-03-14

本文讨论罕见病治疗中药物反应异质性的问题,提出以超强反应和严重伤害为两端表型连续谱,研究其药物基因组学可助力新药开发、合理用药政策及疾病病理理解,并强调在罕见病小样本背景下需结合小数据与大数据方法及国际合作。

要点

  • 罕见病药物反应异质性大,上市前研究难以解释其成因。
  • 研究超强反应与严重伤害两极端表型的药物基因组学具多重价值。
  • 罕见病队列小,应结合小数据与大数据方法并开展国际合作。

核心结论

  • 研究罕见病药物反应两端极端表型的药物基因组学,可助力新药开发、合理用药政策制定及疾病病理理解。

研究设计与样本

  • 本文为综述性文章,讨论药物基因组学在罕见病药物反应研究中的作用与数据策略。

主要发现

  • 罕见病治疗药物的上市前研究数据无法描述治疗反应异质性的原因,导致药物可能比预测更危险或更无效。
  • 以目标线描述药物反应表型连续谱时,两端分别为超强反应和严重伤害。

临床怎么用

  • 在罕见病药物研究中应同步开展药物反应研究,并推动罕见病药物基因组学领域的国际合作。
  • 在队列规模不理想时,应结合小数据与大数据方法进行数据收集与分析以获得最稳健结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rare diseases have become an increasingly important public health priority due to their collective prevalence and often life-threatening nature. Incentive programs, such as the Orphan Drug Act have been introduced to increase the development of rare disease therapeutics. While the approval of these therapeutics requires supportive data from stringent pre-market studies, these data lack the ability to describe the causes of treatment response heterogeneity, leading to medications often being more harmful or less effective than predicted. If a Goal Line were to be used to describe the multifactorial continuum of phenotypic variations occurring in response to a medication, the 'Goal Posts', or the two defining points of this continuum, would be (1) Super-Response, or an extraordinary therapeutic effect; and (2) Serious Harm. Investigation of the pharmacogenomics behind these two extreme phenotypes can potentially lead to the development of new therapeutics, help inform rational use criteria in drug policy, and improve the understanding of underlying disease pathophysiology. In the context of rare diseases where cohort sizes are smaller than ideal, 'small data' and 'big data' approaches to data collection and analysis should be combined to produce the most robust results. This paper presents the importance of studying drug response in parallel to other research initiatives in rare diseases, as well as the need for international collaboration in the area of rare disease pharmacogenomics.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Man A, Groeneweg GSS, Ross CJD, et al. The Role of Pharmacogenomics in Rare Diseases. Drug Saf. 2024. PMID: 38483768. doi:10.1007/s40264-024-01416-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。